Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Advair: Finally Approved, A Long Time Coming

Executive Summary

Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. Scrip's timeline tracks how the commercial value of the drug for GSK has greatly declined from its peak in 2013.

You may also be interested in...



GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US

Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.

GSK's Trelegy On Track To Be First Triple Inhaled Regimen For Asthma

The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.

GSK's New US Pharmaceuticals President Martinez-Davis Brings Oncology Experience

US Pharmaceuticals President Jack Bailey will step down, to be succeeded by Maya Martinez-Davis, currently at Merck KGAA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel